Sandu Pharmaceuticals Ltd
NSE: BSE: 524703
₹38.10
(-1.80%)
Mon, 27 Apr 2026, 10:25 pm
Market Cap374.85M
PE Ratio17.96
Dividend2.06
Health Technology
Pharmaceuticals: Other
24.5KSandu Pharmaceuticals Analysis
dividend
- Unable to evaluate Sandu Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Sandu Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Sandu Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Sandu Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Sandu Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (123.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 6.1x debt.
- Sandu Pharmaceuticals's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (53.6% vs 10.3% today).
- Sandu Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
- Sandu Pharmaceuticals's level of debt (10.3%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Sandu Pharmaceuticals board of directors is about average.
- Umesh's remuneration is about average for companies of similar size in India.
- The tenure for the Sandu Pharmaceuticals management team is about average.
- Umesh's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
misc
- Sandu Pharmaceuticals is not covered by any analysts.
- Sandu Pharmaceuticals has significant price volatility in the past 3 months.
past
- Sandu Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- Sandu Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Sandu Pharmaceuticals used its assets less efficiently than the IN Personal Products industry average last year based on Return on Assets.
- Sandu Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Sandu Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Sandu Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the IN Personal Products industry average.
value
- Sandu Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Sandu Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Sandu Pharmaceuticals is good value based on assets compared to the IN Personal Products industry average.
- Sandu Pharmaceuticals is good value based on earnings compared to the IN Personal Products industry average.
- Sandu Pharmaceuticals is overvalued based on earnings compared to the India market.
- 524703 underperformed the Personal Products industry which returned -5.3% over the past year.
- 524703 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524703 is down -4.1% underperforming the Personal Products industry which returned 3.7% over the past month.
- BSE:524703 is down -4.1% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800